- FDA authorizes StemCells to conduct trial of product candidate in patients with age-related macular degeneration
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA removes clinical hold on trial of Idenix's investigational HCV therapy
- Discovery Labs' aerosol drug delivery system approved
- Merck's Janumet XR approved for type 2 diabetes
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Isotechnika terminates voclosporin agreement with Iljin
What's This?
Isotechnika Pharma Inc. exercised its right to terminate the development, distribution and license agreement it entered into with Iljin Life Science Co. Ltd. regarding voclosporin for transplant and autoimmune indications. As a result, Isotechnika regained the full rights to voclosporin in these indications in the United States and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. The company already held full rights in Europe. "In order to have...
Isotechnika Pharma Inc. exercised its right to terminate the development, distribution and license agreement it entered into with Iljin Life Science Co. Ltd. regarding voclosporin for transplant and autoimmune indications.
As a result, Isotechnika regained the full rights to voclosporin in these indications in the United States and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. The company already held full rights in Europe.
"In order to have more meaningful discussions with Iljin, it was determined that the current contract was not appropriate. Terminating the existing agreement frees [Isotechnika] to engage Iljin, as well as other companies who have expressed interest in voclosporin," said Robert Foster, Isotechnika's chief executive officer. "This action has given the company the opportunity to secure a new, more favorable, relationship to effectively bring voclosporin to the market."
As previously reported, Isotechnika entered into a global development and commercialization license agreement with Vifor Pharma Ltd. in which Vifor received an exclusive license to voclosporin for the treatment of lupus and all proteinuric nephrology indications. The license is applicable in the United States and other territories outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong.
When Isotechnika announced the Vifor license agreement, the company noted that it had reached an agreement with Iljin whereby Iljin licensed back to Isotechnika the autoimmune indications in the countries that fell within Vifor's territory to facilitate the Vifor agreement.
FDA approves label update for Merck's Vytorin to include efficacy data from SHARP trial, does not approve indication for Vytorin, Zetia to help prevent vascular events in patients with CKD 
What's This?
The Food and Drug Administration approved an updated label for Merck & Co. Inc.'s Vytorin (ezetimibe/simvastatin) to include study results from the SHARP trial showing that the combination cholesterol therapy lowers LDL cholesterol levels with fewer major vascular events relative to placebo in patients with moderate to severe chronic kidney disease...
Pfizer, SFJ Pharma to develop axitinib as adjuvant therapy for renal cancer in Asia
What's This?
Pfizer Inc. entered into a collaborative development agreement with SFJ Pharma Ltd. II to conduct a Phase III trial in Asia of Pfizer's axitinib for the adjuvant treatment of patients who are at high risk of recurrent renal cell carcinoma (RCC) after undergoing nephrectomy.The agreement states that SFJ will provide funding and clinical development supervision to generate the clinical data required for...
FDA assigns fast track status to AlloCure's investigational treatment for acute kidney injury
What's This?
AlloCure Inc.'s AC607, an investigational biologic therapy for acute kidney injury (AKI), was granted fast track status by the Food and Drug Administration.The company said Phase I study data showed that the drug had an excellent safety profile and that it appears to be able to reduce both the incidence of AKI and the length of hospital stay in patients who undergo cardiac surgery.
...
Among first-time participants in lab-based wellness program, more than one third discover they have high risk for chronic disease, researchers report
What's This?
Approximately one third of adults who participate for the first time in an employer-based health risk assessment (HRA) program are found to have evidence of at least one common chronic health condition that has not previously been identified, data from a new study shows.The cross-sectional analysis included 52,270 adults aged 20 to 64 years who were first-time participants in an HRA program developed by
American Society of Nephrology 2008 Renal Week
November 4 - 9, 2008 Philadelphia, PA- Kidney stones increase risk of chronic kidney disease, may increase risk of end-stage renal disease in general population, researchers report
- Kidney transplantation may improve cognitive function among patients with ESRD
- Less-frequent dosing of epoetin alfa efficacious in treating anemia in patients with CKD, new data reveal
- Coronary artery bypass surgery may provide improved long-term survival among patients with end-stage renal disease requiring revascularization procedure
- Low potassium level associated with high blood pressure, despite salt intake, CV risk factors
- FDA committee votes in favor of approving Pfizer's Inlyta for advanced RCC
- FDA staff reviewers say Affymax's peginesatide works as well as available anemia products, needs more safety testing
- FDA reviewers question effectiveness of Pfizer's kidney cancer drug candidate
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
- Takeda decides not to market peginesatide in Japan
- FDA approves label update for Merck's Vytorin to include efficacy data from SHARP trial, does not approve indication for Vytorin, Zetia to help prevent vascular events in patients with CKD
- Aveo, Astellas' investigational tivozanib outperforms Bayer, Onyx's Nexavar in kidney cancer trial, data reveal
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
- Isotechnika terminates voclosporin agreement with Iljin
- Among first-time participants in lab-based wellness program, more than one third discover they have high risk for chronic disease, researchers report
